{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-037470","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.017706+00:00","generated_at":"2026-05-15T08:16:26.176206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt","bullets":["Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.","Net loss $3.19M vs $1.77M in 2024; G&A rose to $5.5M from $1.5M on public listing costs.","Phase 2 trial of GX-03 for atopic dermatitis on track; topline results expected mid-2026.","Appointed former CDC Director Dr. Robert Redfield and Martin Dewhurst (ex-McKinsey) to leadership/board.","Entered global license, supply, and distribution agreement with Medline; revenue expected to begin late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-037470","json":"https://secwatch.observer/filing/0001213900-26-037470.json","markdown":"https://secwatch.observer/filing/0001213900-26-037470.md","text":"https://secwatch.observer/filing/0001213900-26-037470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/0001213900-26-037470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/ea0283795-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:16:26.176206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f09fdddef1ed2b8e40f315a8c4e74f44cd602fca","claim":"Turn Therapeutics Inc. reported the year ended December 31, 2025 results: net income NET LOSS $ (3,194,080 ), EPS Basic and diluted net loss per common share $ (0.12 ).","evidence_excerpt":"liability 380,442 - Amortization of deferred offering cost (496,948 ) - Interest income 29,583 28,709 Other income 176,520 - Total other income 2,664,568 28,709 NET LOSS $ (3,194,080 ) $ (1,768,415 ) Basic and diluted net loss per common share $ (0.12 ) $ (0.07 ) Weighted-average common shares outstanding, basic and diluted 27,716,045 26,643,432 Turn","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/0001213900-26-037470-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"NET LOSS $ (3,194,080 )"},{"label":"EPS","value":"Basic and diluted net loss per common share $ (0.12 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}